Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study
about
Profile of certolizumab and its potential in the treatment of psoriatic arthritisTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesAn evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapyInternational patient and physician consensus on a psoriatic arthritis core outcome set for clinical trialsImprovements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised plaAdaptation of Chinese and English versions of the Psoriatic Arthritis Quality of Life (PsAQoL) scale for use in SingaporeEffect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.Psoriatic arthritis: recent progress in pathophysiology and drug development.Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.Certolizumab pegol for the treatment of psoriatic arthritis.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy.A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.Certolizumab pegol for the treatment of psoriasis.Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data.Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.
P2860
Q22305856-B5667513-5E91-4412-A82D-9FAB0A94D8BEQ26764867-CB799E7B-6EC8-45A6-89A8-50EBE707179FQ28074393-0BC4B8DB-BAF1-4808-AB4C-BE658A7E6C84Q30841346-1E7E2878-A00B-4FB7-BB9B-0D0C760A6B2EQ34818891-E1D6E6F0-0F69-48CE-BF4A-11F134F8DF74Q36166729-9877C1CB-2564-40E6-93DB-8BB4549C4354Q36182389-087E51FE-4D5F-4416-A320-4012CAD0597FQ37320545-19F2A4A3-7F52-47A2-8087-8DCED8DB7DB9Q38194559-6D1B2D22-4928-474C-80C4-06A4E8B72BB1Q38219589-4F0974BD-27BB-499A-BA50-94BB5472C591Q38344194-993C91DE-FCA3-41AD-A48A-F867E4E657F3Q38630548-237732E5-6371-46EF-A8AF-929918141B00Q38667430-2C27E78F-2B76-4322-9E26-6CF508C2B52FQ38710469-3A45182D-709E-4FAB-8B50-D148CBEEAD65Q38858335-47F2CB99-5B32-4AE7-BB19-209328D5E462Q38895147-A63E4323-38CD-4817-96FD-A5D3B77A4FE5Q38972531-C28F2EED-D9AC-4E62-A87F-389FA9889060Q38976796-F8F896DE-D9BD-4969-9D98-5583324B2CB0Q45774045-972CA481-0234-48C8-AE8D-333C1846CA12Q47114261-DF48D026-2F0D-4AE8-9B64-F33E08A59744Q47644680-3682D14C-A9CC-4226-8497-1D47DCC57734
P2860
Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effect of certolizumab pegol o ...... a phase III, multicenter study
@ast
Effect of certolizumab pegol o ...... a phase III, multicenter study
@en
Effect of certolizumab pegol o ...... a phase III, multicenter study
@nl
type
label
Effect of certolizumab pegol o ...... a phase III, multicenter study
@ast
Effect of certolizumab pegol o ...... a phase III, multicenter study
@en
Effect of certolizumab pegol o ...... a phase III, multicenter study
@nl
prefLabel
Effect of certolizumab pegol o ...... a phase III, multicenter study
@ast
Effect of certolizumab pegol o ...... a phase III, multicenter study
@en
Effect of certolizumab pegol o ...... a phase III, multicenter study
@nl
P2093
P2860
P356
P1476
Effect of certolizumab pegol o ...... a phase III, multicenter study
@en
P2093
F Woltering
R Fleischmann
P2860
P304
P356
10.1002/ACR.22256
P577
2014-07-01T00:00:00Z